Cutter Capital Management LP Buys Shares of 337,152 NewAmsterdam Pharma (NASDAQ:NAMS)

Cutter Capital Management LP purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 337,152 shares of the company's stock, valued at approximately $8,665,000. NewAmsterdam Pharma makes up approximately 3.6% of Cutter Capital Management LP's holdings, making the stock its 14th biggest holding. Cutter Capital Management LP owned approximately 0.36% of NewAmsterdam Pharma at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in NAMS. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after acquiring an additional 7,199 shares in the last quarter. Geode Capital Management LLC raised its position in shares of NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after purchasing an additional 1,399 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in NewAmsterdam Pharma by 176.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after purchasing an additional 14,280 shares in the last quarter. HB Wealth Management LLC purchased a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $224,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $503,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This trade represents a 90.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James N. Topper acquired 1,135 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. The trade was a 0.04 % increase in their position. The disclosure for this purchase can be found here. Insiders own 19.50% of the company's stock.

NewAmsterdam Pharma Trading Up 1.0 %

NAMS stock opened at $20.24 on Tuesday. The business's 50-day moving average is $19.69 and its 200 day moving average is $21.26. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The stock has a market cap of $2.22 billion, a price-to-earnings ratio of -7.78 and a beta of 0.01.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. As a group, equities analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the company. Needham & Company LLC reiterated a "buy" rating and set a $42.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank upped their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.